Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2017

View Archived Issues

ITUS enters research agreement with Moffitt Cancer Center

European Commission approves Tesaro's Zejula

Genexine's recombinant human erythropoietin effective in patients on dialysis

Selective nSMase2 inhibitor MS-882 shows promise for Alzheimer's disease

Orexo's Zubsolv approved for opioid dependence in Europe

FDA orphan and breakthrough therapy designations awarded to PellePharm for patidegib

FDA grants breakthrough therapy designation to patisiran

Indication for Zytiga expanded in Europe

FDA gives fast track status to lumateperone for treatment of schizophrenia

CX-549's neuroprotective effects demonstrated in a rat model of stroke

OphthaliX completes merger with Wize Pharma

FDA grants orphan drug designation to Revance's daxibotulinumtoxin A for cervical dystonia

Adocia reports phase I results for BioChaperone Glucagon

Melinta Therapeutics presents compounds for treating bacterial infections

Janssen applies to expand indication for Imbruvica in Japan

Novel glucosylceramidase activators presented by Lysosomal Therapeutics

Full U.S. commercial launch for Zilretta

Incyte discloses hPD-1 signaling inhibitors

First patient enrolled in pivotal study of Daiichi Sankyo's DS-8201

EMA announces relocation to the Netherlands

Calliditas Therapeutics gives update on phase III study plans for Nefecon

Calico Life Sciences and AbbVie patent new EIF2B activators

Bayer Pharma identifies vasopressin receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...